A5043045128- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Brain Metastases and Treatment
- Cancer therapeutics and mechanisms
- Multiple and Secondary Primary Cancers
- Cancer Treatment and Pharmacology
- Neuroendocrine Tumor Research Advances
- Radiomics and Machine Learning in Medical Imaging
- Hepatocellular Carcinoma Treatment and Prognosis
- Economic and Financial Impacts of Cancer
- Occupational and environmental lung diseases
- Cancer Diagnosis and Treatment
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Neutropenia and Cancer Infections
- Peptidase Inhibition and Analysis
- PI3K/AKT/mTOR signaling in cancer
- Ferroptosis and cancer prognosis
Centre Léon Bérard
2016-2025
Centre de Recherche en Cancérologie de Lyon
2016-2025
Université Claude Bernard Lyon 1
2012-2025
Dana-Farber Cancer Institute
2025
Université de Lyon
2023
National Cancer Center Hospital East
2023
AstraZeneca (Brazil)
2023
MSD (UK) Limited (United Kingdom)
2023
Boehringer Ingelheim (India)
2023
Daiichi Sankyo (United States)
2023
Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment ALK-positive non-small-cell lung cancer (NSCLC). We investigated alectinib as compared with crizotinib patients previously untreated, advanced NSCLC, including those asymptomatic CNS disease.In randomized, open-label, phase 3 trial, we randomly assigned 303 NSCLC to receive either (600 mg twice daily) or (250 daily). The primary end point...
Human epidermal growth factor receptor 2 (HER2)-targeted therapies have not been approved for patients with non-small-cell lung cancer (NSCLC). The efficacy and safety of trastuzumab deruxtecan (formerly DS-8201), a HER2 antibody-drug conjugate, in
We conducted a phase III study to compare the survival impact of concurrent versus sequential treatment with radiotherapy (RT) and chemotherapy (CT) in unresectable stage non-small-cell lung cancer (NSCLC).Patients were randomly assigned one two arms. In arm, patients received induction CT cisplatin (120 mg/m2) on days 1, 29, 57, vinorelbine (30 mg/m2/wk) from day 1 78, followed by thoracic RT at dose 66 Gy 33 fractions (2 per fraction 5 week). same was started cycles 20 mg/m2/d etoposide 50...
The ALEX study demonstrated significantly improved progression-free survival (PFS) with alectinib versus crizotinib in treatment-naive ALK-positive non-small-cell lung cancer (NSCLC) at the primary data cut-off (9 February 2017). We report mature PFS (cut-off: 30 November 2018) and overall (OS) up to 5 years 29 2019).Patients stage III/IV NSCLC were randomized receive twice-daily 600 mg (n = 152) or 250 151) until disease progression, toxicity, withdrawal death. Primary end point:...
Purpose Comprehensive geriatric assessment (CGA) is recommended to assess the vulnerability of elderly patients, but its integration in cancer treatment decision making has never been prospectively evaluated. Here, patients with advanced non–small-cell lung (NSCLC), we compared a standard strategy chemotherapy allocation on basis performance status (PS) and age an experimental CGA. Patients Methods In multicenter, open-label, phase III trial, ≥ 70 years old PS 0 2 stage IV NSCLC were...
Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has been identified as rare but potentially severe event. Between December 2015 and April 2016, we conducted retrospective study in centres experienced ICI use. We report the main features ICI–ILD with focus on clinical presentation, radiological patterns therapeutic strategies. 64 (3.5%) out 1826 cancer patients...
BackgroundThe phase III ALEX study in patients with treatment-naive advanced anaplastic lymphoma kinase mutation-positive (ALK+) non-small-cell lung cancer (NSCLC) met its primary end point of improved progression-free survival (PFS) alectinib versus crizotinib. Here, we present detailed central nervous system (CNS) efficacy data from ALEX.Patients and methodsOverall, 303 aged ≥18 years underwent 1:1 randomization to receive twice-daily doses 600 mg or crizotinib 250 mg. Brain imaging was...
In approximately 60% of patients with NSCLC who are receiving EGFR tyrosine kinase inhibitors, resistance develops through the acquisition T790M mutation. We aimed to demonstrate that a highly sensitive and quantitative next-generation sequencing analysis mutations from urine plasma specimens is feasible.Short footprint mutation enrichment assays were used interrogate activating in or enrolled TIGER-X (NCT01526928), phase 1/2 clinical study rociletinib previously treated mutant-positive...
IntroductionImmune-checkpoint inhibitor (ICI) efficacy in patients with NSCLC harboring molecular alterations remains poorly elucidated. This study was undertaken to determine ICI against BRAF-, HER2-, MET-, and RET-NSCLC a real-world setting.MethodsIn this retrospective, multicenter ICI-treated MET- or RET-NSCLCs, we analyzed clinical characteristics outcomes: ICI-treatment duration, progression-free survival (PFS), objective response rate, duration of response, overall (OS).ResultsThere...
This phase III study investigated whether continuation maintenance with gemcitabine or switch erlotinib improves clinical outcome compared observation in patients advanced non-small-cell lung cancer (NSCLC) whose disease was controlled after cisplatin-gemcitabine induction chemotherapy.Four hundred sixty-four stage IIIB/IV NSCLC without tumor progression four cycles of were randomly assigned to (1,250 mg/m(2) days 1 and 8 a 3-week cycle) daily (150 mg/day) arms. On progression, all three...
The phase II prospective, noncomparative BRAIN study (NCT00800202) investigated efficacy and safety of bevacizumab in chemotherapy-naïve or pretreated patients with non-small cell lung cancer (NSCLC) asymptomatic untreated brain metastases to provide data this previously unexplored subgroup.Patients stage IV nonsquamous NSCLC, Eastern Cooperative Oncology Group performance status 0-1, untreated, received first-line (15 mg/kg) plus carboplatin (area under the curve ×6) paclitaxel (200...
To further characterize survival benefit with first-line nivolumab plus ipilimumab two cycles of chemotherapy versus alone, we report updated data from the phase III CheckMate 9LA trial a 2-year minimum follow-up.
Trastuzumab deruxtecan (T-DXd) 5.4 and 6.4 mg/kg showed robust antitumor activity in multiple cancer indications; however, T-DXd has not been evaluated patients with previously treated human epidermal growth factor receptor 2-mutant (
Selpercatinib, a highly selective potent and brain-penetrant RET inhibitor, was shown to have efficacy in patients with advanced fusion–positive non–small-cell lung cancer (NSCLC) nonrandomized phase 1–2 study. Download PDF of the Research Summary. In randomized 3 trial, we evaluated safety first-line selpercatinib as compared control treatment that consisted platinum-based chemotherapy or without pembrolizumab at investigator's discretion. The primary end point progression-free survival...
LBA9000 Background: EGFR TKIs are standard 1L therapy for metastatic NSCLC with sensitizing mutations; however, most patients (pts) ultimately experience PD. We report the protocol-specified final analysis (FA) from randomized, double-blind, phase 3 KEYNOTE-789 study of pemetrexed (pem) and platinum-based chemotherapy (chemo) or without pembrolizumab (pembro) as subsequent pts TKI-resistant, EGFR-mutant, nonsquamous (NCT03515837). Methods: Adults histologically cytologically confirmed stage...
PURPOSE Epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for -mutant, metastatic non–small cell lung cancer (NSCLC); however, most patients experience disease progression. We report results from the randomized, double-blind, phase III KEYNOTE-789 study of pemetrexed and platinum–based chemotherapy with or without pembrolizumab TKI-resistant, nonsquamous NSCLC (ClinicalTrials.gov identifier: NCT03515837 ). METHODS Adults...
PURPOSE The randomized, open-label, global phase III TROPION-Lung01 study compared the efficacy and safety of datopotamab deruxtecan (Dato-DXd) versus docetaxel in patients with pretreated advanced/metastatic non–small cell lung cancer (NSCLC). METHODS Patients received Dato-DXd 6 mg/kg or 75 mg/m 2 once every 3 weeks. Dual primary end points were progression-free survival (PFS) overall (OS). Objective response rate, duration response, secondary points. RESULTS In total, 299 305 randomly...